CoreWeave (CRWV) Stock Slides 3% Amid Meta Competition Fears and Heavy Insider Selling

Key Takeaways

• CoreWeave shares declined 3.4% to close at $83.53, touching an intraday bottom of $79.46, while volume trailed the daily average by 20%
• Analysts hold a Moderate Buy rating with a consensus price target of $135, with bullish forecasts reaching as high as $250
• Investor anxiety is mounting over Meta’s reported plans to enter the AI cloud computing space, potentially challenging CoreWeave’s market position
• Company insiders have offloaded more than $3 billion in shares over the last three months, primarily through tax withholding arrangements
• The company’s Q1 results fell short of expectations with EPS of -$1.40 versus the -$1.17 estimate, despite revenue jumping 111.6% annually to $2.08 billion

CoreWeave (CRWV) experienced a 3.4% pullback on Tuesday, settling at $83.53 following an intraday descent to $79.46. The previous trading session had concluded at $86.46.

CoreWeave, Inc. Class A Common Stock, CRWV

Trading activity registered approximately 23 million shares, falling roughly 20% short of typical volumes — indicating the downturn wasn’t fueled by mass liquidation.

Year-to-date, the stock maintains a 26% gain, though it’s nursing a 41% decline over the trailing twelve months and trading considerably beneath its 50-day moving average of $106.86.

Tuesday’s weakness reflected mounting investor apprehension centered on two key issues: Meta’s reported AI computing infrastructure ambitions and persistent insider share dispositions.

A Bloomberg piece highlighted Meta’s exploration of commercializing AI computing services and infrastructure capacity to external clients — a strategic direction that would place it squarely against CoreWeave’s primary revenue streams.

Rosenblatt upheld its Buy stance with a $250 target, contending the Meta threat is exaggerated. Both Wolfe Research and Evercore ISI confirmed Outperform positions with matching $150 targets.

Executive Stock Dispositions Draw Attention

Insider transactions have become a focal point. Throughout the preceding 90 days, company insiders have divested more than $3 billion in CRWV shares.

Most recently, General Counsel Kristen J. McVeety disposed of 22 shares for $1,889 on July 6, conducted under a Rule 10b5-1 arrangement established in May 2025.

Prior to that, insider Brian Venturo unloaded 76,912 shares on July 1 at an average price of $86.99, generating approximately $6.69 million. This transaction trimmed his holdings by 21%.

Insider Brannin McBee divested 56,707 shares on June 30 at $95.69, totaling roughly $5.43 million — reducing his stake by 14.9%.

Both transactions occurred through predetermined Rule 10b5-1 arrangements designed to satisfy tax liabilities on equity compensation vesting. While this represents standard practice, the magnitude has nonetheless attracted market attention.

Recent Earnings Disappointment Lingers

CoreWeave’s most recent quarterly disclosure on May 7 added to sentiment headwinds. The firm recorded EPS of -$1.40, falling short of the -$1.17 consensus projection by $0.23.

Revenue reached $2.08 billion, representing 111.6% year-over-year expansion. While top-line momentum remains robust, profitability challenges persist — the net margin currently registers at -25.57%.

Wall Street’s consensus forecast anticipates full-year EPS of -$4.57.

Notwithstanding the earnings shortfall, multiple analysts contend the sell-off is excessive. BNP Paribas holds the Street’s most optimistic target at $192, with Cantor Fitzgerald at $167. Wells Fargo elevated its objective to $155 in May.

Among 35 analysts tracking the equity, 21 assign Buy ratings, 12 recommend Hold, and 2 suggest Sell.

The company’s debt-to-equity ratio registers at 3.68, accompanied by a current ratio of merely 0.31 — a financial structure that introduces meaningful risk alongside the growth narrative.

CoreWeave’s market capitalization hovers between approximately $37–45 billion, fluctuating with market conditions. The company unveiled ARIA, an AI-powered research assistant, earlier this week — though analysts view it as lacking immediate catalytic potential.